Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease

Experimental Neurology
Marta Garcia-MirallesMahmoud A Pouladi

Abstract

Abnormal monoamine oxidase A and B (MAO-A/B) activity and an imbalance in monoamine neurotransmitters have been suggested to underlie the pathobiology of depression, a major psychiatric symptom observed in patients with neurodegenerative diseases, such as Huntington disease (HD). Increased MAO-A/B activity has been observed in brain tissue from patients with HD and in human and rodent HD neural cells. Using the YAC128 mouse model of HD, we studied the effect of an irreversible MAO-A inhibitor, clorgyline, on the levels of select monoamine neurotransmitters associated with affective function. We observed a decrease in striatal levels of the MAO-A/B substrates, dopamine and norepinephrine, in YAC128 HD mice compared with wild-type mice, which was accompanied by increased anxiety- and depressive-like behaviour at five months of age. Treatment for 26 days with clorgyline restored dopamine, serotonin, and norepinephrine neurotransmitter levels in the striatum and reduced anxiety- and depressive-like behaviour in YAC128 HD mice. This study supports a potential therapeutic use for MAO-A inhibitors in the treatment of depression and anxiety in patients with HD.

References

Jan 1, 1985·Neuroscience and Biobehavioral Reviews·J N Crawley
Aug 11, 1973·Lancet·N V Manyam
Nov 3, 1998·Human Genetics·S Z SabolD Hamer
Aug 6, 1999·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·J H ChaA B Young
Apr 12, 2003·Brain : a Journal of Neurology·Nicola PavesePaola Piccini
Jun 19, 2003·Human Molecular Genetics·Elizabeth J SlowMichael R Hayden
Sep 3, 2005·Nature Reviews. Drug Discovery·John F Cryan, Andrew Holmes
Jan 3, 2006·The Journal of Neuropsychiatry and Clinical Neurosciences·Jane S PaulsenBeth Turner
Jan 13, 2006·British Journal of Pharmacology·Moussa B H Youdim, Y S Bakhle
Mar 23, 2006·Nature Reviews. Neuroscience·Moussa B H YoudimKeith F Tipton
Aug 23, 2006·Nature Reviews. Neuroscience·Jess Nithianantharajah, Anthony J Hannan
Apr 5, 2007·Nature Protocols·Alicia A Walf, Cheryl A Frye
Dec 12, 2007·The Journal of Neuropsychiatry and Clinical Neurosciences·E van DuijnR C van der Mast
Feb 9, 2008·Trends in Neurosciences·Joshua W Buckholtz, Andreas Meyer-Lindenberg
Jun 13, 2009·Cellular and Molecular Life Sciences : CMLS·Cristina LanniCinzia Boselli
Oct 27, 2009·Neurobiology of Disease·Nicola PavesePaola Piccini
Sep 30, 2010·Neurobiology of Disease·Jessica M SimpsonBrian R Christie
Apr 13, 2011·PloS One·Fanny MochelRaphael Schiffmann
Jul 29, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Chi-Tso ChiuDe-Maw Chuang
Aug 15, 2012·Drug Discoveries & Therapeutics·Jeremy DuncanXiao-Ming Ou
Sep 6, 2012·Epigenetics : Official Journal of the DNA Methylation Society·Elena ShumayJoanna S Fowler
Apr 23, 2013·Progress in Neuro-psychopharmacology & Biological Psychiatry·Michel Hamon, Pierre Blier
May 17, 2013·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Karim Ben M'BarekSandrine Humbert
Jul 13, 2013·Frontiers in Neuroscience·Jane Y ChenMichael S Levine
Sep 21, 2013·Nature Reviews. Neuroscience·Mahmoud A PouladiMichael R Hayden
Oct 16, 2014·Pharmacology, Biochemistry, and Behavior·Thibault RenoirAnthony J Hannan
Aug 2, 2015·Cell·UNKNOWN Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium
Aug 15, 2015·Annals of Clinical and Translational Neurology·Herminia D RosasSteven M Hersch

❮ Previous
Next ❯

Citations

Sep 22, 2018·Nature Reviews. Drug Discovery·Nicholas S CaronMichael R Hayden
Mar 9, 2018·Journal of Neural Transmission·Rona R Ramsay, Alen Albreht
Jan 11, 2020·Movement Disorders : Official Journal of the Movement Disorder Society·Parunyou JulayanontNikolaus R McFarland
Mar 23, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Jiancheng WangZhenyu Wang
Aug 2, 2019·Journal of Clinical Movement Disorders·Elvina May-Yin ChuCaroline Knight
Jul 25, 2018·Current Protocols in Neuroscience·Claudia Rangel-Barajas, George V Rebec
Jul 3, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Derya OsmaniyeGülhan Turan
Jun 24, 2020·Behavioural Brain Research·Arianna NovatiHuu Phuc Nguyen
Jun 12, 2020·Neurobiology of Disease·Carolina GubertAnthony J Hannan
Jun 9, 2021·Bioorganic Chemistry·Fatih TokBedia Koçyiğit-Kaymakçıoğlu
Mar 17, 2021·Brain : a Journal of Neurology·Negin HollandJames B Rowe

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Barrel cortex

Here is the latest research on barrel cortex, a region of somatosensory and motor corticies in the brain, which are used by animals that rely on whiskers for world exploration.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.